Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Allen A, Rao Krishna, Singh Prashant, Fehlman Jared, Gao Jun, Takakura Will, Lynett Amanda, Haller Emily, Ball Sarah, Marand Alicia, Liu Amy, Shah Eric, Menees Stacy, Punglia Raani, Nojkov Borko, Eswaran Shanti, Baker Jason, Chey William D, Owyang Chung, Young Vincent, Hasler William L
Аннотация
BACKGROUND & AIMS: The low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet (LFD) and rifaximin are effective in <50% individuals with irritable bowel syndrome (IBS), highlighting the need to identify predictors of treatment response. We therefore conducted a randomized controlled trial comparing LFD and rifaximin to identify microbial predictors of response.
METHODS: Sixty-five adults with diarrhea-predominant IBS (IBS-D) were randomized to LFD or rifaximin for 5 weeks. Primary endpoints were changes in mean daily abdominal pain and bloating at week 5 vs baseline. Secondary endpoints included changes in IBS Symptom Severity Score and Bristol Stool Form Scale at week 5 vs baseline. Exploratory endpoints included responders defined as ≥30% reduction in abdominal pain or bloating. Stool samples collected at weeks 0, 2, 4, and 5 underwent 16S rRNA sequencing, and glucose breath testing (BT) was performed at weeks 0 and 5.
RESULTS: Both LFD and rifaximin significantly improved abdominal pain (-0.29 with LFD vs -0.24 points/week with rifaximin); bloating (-0.29 vs -0.19 per week); and IBS Symptom Severity Score (-14.2 vs -13.3 per week) at week 5 (all P < .0001), with no significant change in Bristol Stool Form Scale. BT results were inconsistent predictors of response, with positive baseline hydrogen BT associated with lower odds of rifaximin response, and methane conversion at week 5 showed discordant associations with rifaximin response. In contrast, distinct baseline taxa were associated with treatment response. LFD responders had lower abundance of putative saccharolytic taxa (Butyricimonas, Bacteroides, Intestinibacter), whereas rifaximin responders were enriched in taxa with putative short-chain fatty acid-producing and bile acid-modifying potential (Ruminococcus, Coprococcus, Odoribacter). Nonresponders exhibited enrichment of putative proteolytic taxa (Bilophila, Alistipes, Prevotella).
CONCLUSIONS: LFD and rifaximin are equally effective for IBS-D, with distinct microbial predictors of response. However, these findings require validation before informing personalized treatment approaches.
CLINICALTRIALS: gov, Number: NCT03219528.
METHODS: Sixty-five adults with diarrhea-predominant IBS (IBS-D) were randomized to LFD or rifaximin for 5 weeks. Primary endpoints were changes in mean daily abdominal pain and bloating at week 5 vs baseline. Secondary endpoints included changes in IBS Symptom Severity Score and Bristol Stool Form Scale at week 5 vs baseline. Exploratory endpoints included responders defined as ≥30% reduction in abdominal pain or bloating. Stool samples collected at weeks 0, 2, 4, and 5 underwent 16S rRNA sequencing, and glucose breath testing (BT) was performed at weeks 0 and 5.
RESULTS: Both LFD and rifaximin significantly improved abdominal pain (-0.29 with LFD vs -0.24 points/week with rifaximin); bloating (-0.29 vs -0.19 per week); and IBS Symptom Severity Score (-14.2 vs -13.3 per week) at week 5 (all P < .0001), with no significant change in Bristol Stool Form Scale. BT results were inconsistent predictors of response, with positive baseline hydrogen BT associated with lower odds of rifaximin response, and methane conversion at week 5 showed discordant associations with rifaximin response. In contrast, distinct baseline taxa were associated with treatment response. LFD responders had lower abundance of putative saccharolytic taxa (Butyricimonas, Bacteroides, Intestinibacter), whereas rifaximin responders were enriched in taxa with putative short-chain fatty acid-producing and bile acid-modifying potential (Ruminococcus, Coprococcus, Odoribacter). Nonresponders exhibited enrichment of putative proteolytic taxa (Bilophila, Alistipes, Prevotella).
CONCLUSIONS: LFD and rifaximin are equally effective for IBS-D, with distinct microbial predictors of response. However, these findings require validation before informing personalized treatment approaches.
CLINICALTRIALS: gov, Number: NCT03219528.